Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.

@article{Sutton2015PersistentMB,
  title={Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.},
  author={Rosemary Sutton and Peter A. Shaw and Nicola C. Venn and Tamara Law and Anuruddhika Dissanayake and Tatjana Kilo and Michelle Haber and Murray D. Norris and Chris Fraser and Frank Alvaro and Tamas R Revesz and Toby Nicholas Trahair and Luciano Dalla-Pozza and Glenn M. Marshall and Tracey O'Brien},
  journal={British journal of haematology},
  year={2015},
  volume={168 3},
  pages={395-404}
}
Minimal residual disease (MRD) during early chemotherapy is a powerful predictor of relapse in acute lymphoblastic leukaemia (ALL) and is used in children to determine eligibility for allogeneic haematopoietic stem cell transplantation (HSCT) in first (CR1) or later complete remission (CR2/CR3). Variables affecting HSCT outcome were analysed in 81 children from the ANZCHOG ALL8 trial. The major cause of treatment failure was relapse, with a cumulative incidence of relapse at 5 years (CIR) of 32… CONTINUE READING